The US FDA issues EUA for Johnson & Johnson’s single-dose COVID-19 vaccine

The US Food and Drug Administration (FDA) has issued emergency use authorisation for Johnson & Johnson’s single-dose COVID-19 vaccine.

The authorisation swiftly followed a positive meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee, which unanimously backed a EUA for the jab.

Briefing documents that were published endorsed the efficacy and safety of the vaccine and reiterated its effectiveness of sixty-six-point-one per cent in a Phase III trial.

J&J stated that it’s expecting to distribute one-hundred million single-dose vaccines to the US during the first six months of 2021.

Chief scientific officer, J&J, Paul Stoffels, stated: “We believe the Johnson & Johnson single-shot COVID-19 vaccine is a critical tool for fighting this global pandemic, particularly as it shows protection across countries with different variants. A vaccine that protects against COVID-19, especially against the most dire outcomes of hospitalisation and death, will help ease the burden on people and the strain on health systems worldwide.”